¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ventricular activation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ventricular
    1. ½É½Ç- 2. ³ú½Ç-
  • ventricular aneurysm
    ½É½ÇÀÚ·ç, ½É½Ç·ù
  • ventricular arrhythmia
    ½É½ÇºÎÁ¤¸Æ
  • ventricular asynergy
    ½É½ÇÇùµ¿ºÒ´É(Áõ)
  • ventricular bulge
    ½É½ÇÆØÃ¢
  • ventricular capture
    ½É½ÇÆ÷Âø
  • ventricular catheter
    ³ú½Çµµ°ü, ³ú½ÇÄ«Å×ÅÍ
  • ventricular compliance
    ½É½Çź¼º
  • ventricular diastole
    ½É½ÇÈ®Àå±â
  • ventricular ejection
    ½É½Ç¹ÚÃâ
  • ventricular enlargement
    1. ³ú½ÇÈ®Àå 2. ½É½ÇÈ®Àå
  • ventricular escape
    ½É½Ç¼ºÀÌÅ»¹Úµ¿
  • ventricular extrasystole
    ½É½ÇÁÖ±â¿Ü¼öÃà, ½É½Ç±â¿Ü¼öÃà
  • ventricular fibrillation
    ½É½Ç¼¼µ¿, ½É½ÇÀܶ³¸²
  • ventricular flutter
    ½É½ÇÁ¶µ¿, ½É½ÇµÈ¶³¸²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • combined ventricular hypertrophy
    º¹ÇսɽǺñ´ë
  • escaped ventricular contraction
    ÀÌÅ»½É½Ç¼öÃà
  • premature ventricular contraction
    Á¶±â½É½Ç¼öÃà, ½É½Ç±â¿Ü¼öÃà
  • ventricular capture
    ½É½ÇÆ÷Âø
  • ventricular catheter
    ³ú½ÇµµÀÚ, ³ú½Çµµ°ü
  • ventricular compliance
    ½É½Çź¼º
  • ventricular diastole
    ½É½ÇÀÌ¿Ï, ½É½ÇÈ®Àå
  • ventricular septal defect
    ½É½Ç»çÀ̸·°á¼Õ, ½É½ÇÁ߰ݰá¼Õ
  • ventricular ejection
    ½É½Ç¹ÚÃâ
  • ventricular enlargement
    ³ú½ÇÈ®Àå, ½É½ÇÈ®Àå
  • ventricular escape
    ½É½Ç¼ºÀÌÅ»
  • ventricular extrasystole
    ½É½ÇÁÖ±â¿Ü¼öÃà
  • left ventricular failure
    ¿Þ½É½Ç±â´É»ó½Ç, Á½ɽǺÎÀü
  • right ventricular failure
    ¿À¸¥½É½Ç±â´É»ó½Ç, ¿ì½É½ÇºÎÀü
  • ventricular fibrillation
    ½É½ÇÀܶ³¸², ½É½Ç¼¼µ¿
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • heat of activation
    Ȱ¼ºÈ­¿­(üÀàõûýæð)
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • islet-activation factor
    ¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
  • macrophage,activation of
    Ȱ¼ºÈ­(üÀàõûù)
  • neutron activation analysis
    Áß¼ºÀÚ¹æ»çÈ­ºÐ¼®(~Û¯ÞÒûùÝÂà°).
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • sleep activation
    ¼ö¸éºÎȰ(¹ý)(¡­Ý¥üÀÛö) ³úÆÄ(Òà÷î)ÀÇ .
  • thermal activation
    ¿­È°¼ºÈ­¹ÝÀÀ(æðüÀàõûù Úãëë).
  • tissue plasminogen activation
    Á¶Á÷ ÇöóÁî¹Ì°Õ Ȱ¼º
  • tissue plasminogen activation inhibitor
    Á¶Á÷ ÇöóÁî¹Ì³ë°Õ Ȱ¼º ¾ïÁ¦ÀÎÀÚ
  • trypsinogen activation peptide(TAP)
  • aortic left ventricular tunnel
    ´ëµ¿¸ÆÁ½ɽǰ£Åë·Î.
  • asymmetric ventricular hypertrophy
    ºñ´ëμº ½É½Çºñ´ëÁõ.
  • automatic ventricular contraction
    ÀÚµ¿½É½Ç¼öÃà(¡­ãýãøâ¥õê).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AMI Acute Myocardial Infarction
  - Complications(Cx)
    1. Early ...
VF left leg [electrode]; ventricular fibrillation; ventricular fluid; ventricular flutter; visual field...
RAS   1) Reticular Activating(Activation) System
  2) Renal Artery Stenosis
ADR activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ...
AE above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ARI activation recovery interval
AT Activation time
Ea Energy of activation
FAP Fibroblast Activation Protein
HIPA Heparin-induced platelet activation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • left ventricular ejection time
    Á ½É½Ç ±¸Ç÷ ±â°£
  • left ventricular end-diastolic volume
    Á ½É½Ç À̿ϱ⸻ ¿ëÀû
  • left ventricular failure
    Á ½É½Ç ºÎÀü
  • left ventricular outflow tract stenosis
    Á ½É½Ç À¯Ãâ·Î ÇùÂø
  • left ventricular pressure
    Á ½Ç¾Ð, Á ½É½Ç ¾Ð
    Á ½É½Ç¿¡¼­ ´ëµ¿¸ÆÀ¸·Î ÇǸ¦ º¸³»°Ô ÇÏ´Â ¿øµ¿·Â.
  • left ventricular strain
    ÁÂ½Ç ±äÀå, ÁÂ½É½Ç ±äÀå
  • right ventricular failure
    ¿ì ½É½Ç ºÎÀü
  • right ventricular hypertrophy
    ¿ì ½É½Ç ºñ´ë
  • right ventricular strain
    ¿ì ½É½Ç ±äÀå
  • ventricular
    ½É½ÇÀÇ
    ½É½Ç¿¡ °üÇÑ.
  • ventricular fibrillation
    ½É½Ç ¼¼µ¿
    ½ÉÀåÀÇ ¹Úµ¿¿¡¼­ ½É½ÇÀÇ °¢ ºÎºÐÀÌ ¹«Áú¼­ÇÏ°Ô ºÒ±ÔÄ¢ÀûÀ¸·Î ¼öÃàÇÏ´Â »óÅÂ. ¼öÃàÀÇ ºóµµ, Áï ½ÉÀüµµ»óÀÇ ÆÄ»óÀÌ ¸ÅºÐ 170¡­300ÀÎ °ÍÀ» Á¶µ¿, 300¡­600ÀÎ °ÍÀ» ¼¼µ¿À̶ó ÇÏ¿© ±¸º°ÇÏ´Â °æ¿ìµµ ÀÖÀ¸³ª, ½É½Ç Á¶µ¿¿¡´Â Áֱ⿡ È®½ÇÇÑ ±ÔÄ¢¼ºÀÌ ¾øÀ¸¹Ç·Î ½É½Ç¿¡ °üÇÏ¿© ¼¼µ¿°ú Á¶µ¿ »çÀÌ¿¡´Â ¶Ñ·ÇÇÑ ±¸º°ÀÌ ¾ø´Ù. ½É½Ç ¼¼µ¿ÀÏ ¶§´Â ½É½Ç¿¡¼­ Ç÷¾×ÀÌ ¹ÚÃâµÇÁö ¾ÊÀ¸¹Ç·Î ¼øÈ¯ºÎÀüÀ» ÀÏÀ¸ÄѼ­ »ç¸ÁÇÏ°Ô µÈ´Ù. À̶§´Â ½ÉÀå ¸¶»çÁö¸¦ Çϰųª Á¦¼¼µ¿±â¿¡ ÀÇÇÏ¿© ¼¼µ¿À» Á¦°ÅÇØ¾ß ÇÑ´Ù.
  • ventricular gallop
    ½É½Ç¼º °¶·´, ½É½Ç¼º ºÐ¸¶À²
  • ventricular septal defect
    ½É½Ç Áß°Ý °á¼Õ
    ¼±Ãµ¼º ½ÉÁúȯ¿¡¼­ ºóµµ°¡ ³ôÀº °ÍÀÇ ÇϳªÀÌ´Ù. ½É½Ç Áß°Ý¿¡ °á¼ÕÀÌ ÀÖ´Â °ÍÀ» ¸»ÇÑ´Ù. º¸Åë ½É½Ç Áß°Ý ¸·¼º ºÎÀ§ÀÇ °á¼ÕÀε¥ ±Ù¼º ºÎÀ§¿¡ °á¼ÕÀÌ ÀÖ´Â °Íµµ ÀÖ´Ù. °á¼Õ°øÀÇ Å©±â´Â ´Ù¾çÇÏ´Ù. ÀϹÝÀûÀ¸·Î ¿¹ÈÄ´Â ¾çÈ£Çϰí ÀÚ¿¬ Æó¼âµµ ÀÖ´Ù. Ä¡·á´Â ¿Ü°úÀûÀ¸·Î Æó¼â¸¦ ÇÑ´Ù.
  • ventricular vein
    ½É½Ç Á¤¸Æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
energy of activation Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature.
(05 Mar 2000)
enzyme activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
(12 Dec 1998)
juxtacrine activation Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface.
(18 Nov 1997)
feedback activation The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting.
(05 Mar 2000)
feed-forward activation The activation of an enzyme by a precursor of the substrate of that enzyme.
(05 Mar 2000)
upstream activation site A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter.
(09 Oct 1997)
low-activation materials <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide.
(09 Oct 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
aberrant ventricular conduction Abnormal intraventricular conduction of a supraventricular beat, especially where surrounding beats are normally conducted.
Synonym: ventricular aberration.
(05 Mar 2000)
aortico-left ventricular tunnel Congenital connection between the aorta above exit of coronary arteries and the left ventricle.
(05 Mar 2000)
arrhythmias, ventricular Abnormal rapid heart rhythms (arrhythmias) that originate in the lower chambers of the heart (the ventricles). Ventricular arrhythmias include ventricular tachycardia and ventricular fibrillation. Both are life threatening arrhythmias most commonly associated with heart attacks or scarring of the heart muscle from previous heart attack.
(12 Dec 1998)
arrhythmogenic right ventricular dysplasia A congenital cardiomyopathy in which transmural infiltration of adipose tissue results in weakness and aneurysmal bulging of the infundibulum, apex, and posterior basilar region of the right ventricle and leads to ventricular tachycardia arising in the right ventricle.
(12 Dec 1998)
atrial ventricular canal defect A defect caused by deficient or absent septal tissue immediately above and below the normal level of the atrioventricular valves, including the region normally occupied by the A-V septum in hearts with two ventricles. The A-V valves are abnormal to a varying degree.
(05 Mar 2000)
bidirectional ventricular tachycardia Ventricular tachycardia in which the QRS complexes in the electrocardiogram are alternately mainly positive and mainly negative; many such cases may represent ventricular tachycardia with alternating forms of aberrant ventricular conduction.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á